```html

Microscopic Colitis: A Complete Patient‑Friendly Guide

Overview

Microscopic colitis (MC) is an inflammatory condition of the colon that gets its name because the colon looks normal during a routine colonoscopy, but the disease is detectable under a microscope. There are two main subtypes:

• Lymphocytic colitis (LC) – characterized by an increased number of lymphocytes (a type of white blood cell) in the lining of the colon.
• Collagenous colitis (CC) – marked by a thickened collagen (protein) layer just beneath the colon lining.

Both subtypes present with similar symptoms, most notably chronic watery diarrhea.

Who is affected?

• Adults over 55 years old are most commonly affected, but cases have been reported in children and younger adults.
• Women are about twice as likely as men to develop MC.
• People of any ethnicity can develop the condition, though data from the United States and Europe suggest slightly higher rates in Caucasian populations.

Prevalence

Recent epidemiologic studies estimate an incidence of 5–15 cases per 100,000 persons per year and a prevalence of ≈100–200 per 100,000 (≈0.1–0.2 % of the general population). The numbers appear to be rising, likely because of increased awareness and more frequent use of colonoscopic biopsies.<sup>1</sup>

---

Symptoms

The hallmark of microscopic colitis is chronic watery diarrhea, but a range of related symptoms can occur. Symptoms may wax and wane and can be triggered by meals, medications, or stress.

• Watery diarrhea – usually non‑bloody, occurring 3–10+ times per day. Stools are often described as “salty” or “pasty.”
• Urgency – a sudden, compelling need to have a bowel movement.
• Nocturnal diarrhea – waking up at night to defecate, which is less common in other diarrheal disorders.
• Abdominal cramping or discomfort – mild to moderate, often relieved after a bowel movement.
• Bloating and gas – due to rapid transit of stool.
• Weight loss – generally modest (5–10 % of body weight) unless disease is severe or associated with malabsorption.
• Fatigue – secondary to fluid loss, electrolyte imbalance, or sleep disruption.
• Nausea – less common, but reported in up to 15 % of patients.
• Peripheral edema – rare, may result from severe hypo‑albuminemia in prolonged disease.

Symptoms typically persist for months to years and may improve spontaneously, but most patients require treatment for quality‑of‑life reasons.

---

Causes and Risk Factors

Underlying Mechanisms

The exact cause of microscopic colitis is unknown, but research points to an abnormal immune response in the colon’s lining. Possible mechanisms include:

• Autoimmune dysregulation – the body’s immune system attacks the colon lining, leading to lymphocytic infiltration or collagen deposition.
• Medication‑induced injury – several drugs have been linked to MC, possibly by altering gut permeability or triggering immune activation.
• Microbial factors – alterations in the gut microbiome (dysbiosis) may play a role, though evidence is still emerging.
• Genetic predisposition – family clustering suggests a hereditary component, but specific genes have not been definitively identified.

Risk Factors

• Medications – Non‑steroidal anti‑inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), antihistamines, and certain antibiotics have been implicated.<sup>2</sup>
• Autoimmune diseases – Patients with rheumatoid arthritis, celiac disease, thyroiditis, or psoriasis have higher odds of MC.
• Smoking – Current smokers have up to a 2‑fold increased risk compared with never‑smokers.
• Female gender & older age – As noted above.
• Infections – A preceding gastrointestinal infection can precede onset in a minority of cases.

---

Diagnosis

Clinical Evaluation

Because the colon appears normal on endoscopy, a high index of suspicion is needed. Your physician will:

1. Take a detailed history (duration of diarrhea, medication list, associated autoimmune disorders, smoking status).
2. Perform a physical exam focusing on abdominal tenderness, dehydration signs, and nutritional status.

Diagnostic Tests

• Colonoscopy with biopsies – The gold standard. Multiple random biopsies (usually ≥6) are taken from the right, transverse, and left colon. Histology distinguishes LC (≥20 intraepithelial lymphocytes per 100 epithelial cells) from CC (collagen band >10 µm).<sup>3</sup>
• Stool studies – Rule out infectious causes (culture, PCR for C. difficile, ova & parasites). Fecal calprotectin is often normal in MC, helping differentiate from inflammatory bowel disease.
• Blood tests – CBC (to detect anemia), CMP (electrolytes), CRP/ESR (usually normal or mildly elevated), thyroid function, and autoantibodies if an autoimmune link is suspected.
• Imaging – Not routinely required, but abdominal CT may be ordered if another intra‑abdominal process is suspected.

Diagnostic Criteria (per 2022 Consensus)

1. Chronic watery diarrhea lasting ≥4 weeks.
2. Normal colonoscopic appearance.
3. Histologic evidence of either lymphocytic or collagenous colitis.
4. Exclusion of alternative causes (infection, medication side‑effects, other IBD).

---

Treatment Options

First‑line Medications

• Bud­esonide – A locally active glucocorticoid with minimal systemic absorption. Typical dose is 9 mg daily for 8 weeks, then taper. Clinical trials show remission rates of 70‑80 %.<sup>4</sup>
• Antidiarrheal agents – Loperamide (Imodium) or diphenoxylate/atropine can control stool frequency, especially while waiting for budesonide to take effect.

Second‑line / Maintenance Therapy

• Low‑dose budesonide – 3–6 mg daily for long‑term maintenance in patients with frequent relapses.
• Immunomodulators – Azathioprine or 6‑mercaptopurine may be considered for steroid‑dependent disease.
• Biologics – Anti‑TNF agents (infliximab) and anti‑integrin therapy (vedolizumab) have shown benefit in refractory cases, though data are limited.
• Rifaximin – A non‑absorbable antibiotic sometimes used when dysbiosis is suspected.

Lifestyle & Dietary Interventions

• Identify trigger medications – Discontinue or substitute NSAIDs, PPIs, SSRIs if feasible.
• Smoking cessation – Improves outcomes and reduces recurrence.
• Dietary modifications – While no single diet cures MC, many patients benefit from:
  • Low‑FODMAP diet to reduce fermentable carbohydrate load.
  • Gluten‑free diet if celiac disease is present or if symptoms improve with trial.
  • Limiting high‑fat meals, caffeine, and alcohol, which can exacerbate diarrhea.
• Hydration & electrolytes – Replace fluids with oral rehydration solutions or sports drinks containing sodium and potassium.

Procedural Options

Procedures are rarely needed, but in severe, refractory cases colonoscopic “balloon‑dilatation” or surgical resection of a localized segment has been reported. These are considered last‑resort measures.

---

Living with Microscopic Colitis

Day‑to‑Day Management

• Medication adherence – Take budesonide exactly as prescribed; do not stop abruptly without discussing tapering.
• Track symptoms – Use a bowel diary (frequency, consistency, triggers) to discuss with your provider.
• Plan for outings – Know the locations of restrooms and carry a small “diarrhea kit” (toilet paper, wipes, a change of underwear).
• Nutrition – Small, frequent meals, avoid large fatty meals. Consider a probiotic (e.g., Lactobacillus rhamnosus GG) after discussion with your doctor.
• Exercise – Light to moderate activity is encouraged; stay hydrated.
• Stress management – Techniques such as deep breathing, yoga, or cognitive‑behavioral therapy can lessen symptom flares.

Follow‑up Care

After initial treatment, most clinicians schedule a follow‑up colonoscopy with biopsies 3–6 months later to confirm histologic remission. Long‑term monitoring includes:

• Annual assessment of bone health if chronic steroids were used.
• Periodic labs (CBC, CMP) to check for anemia or electrolyte disturbances.
• Re‑evaluation of medication side‑effects.

---

Prevention

Because the precise cause is unclear, prevention focuses on modifiable risk factors:

• Avoid unnecessary NSAIDs and PPIs – Use the lowest effective dose, or discuss alternatives with your physician.
• Quit smoking – Seek counseling, nicotine replacement, or prescription medications.
• Maintain a balanced gut microbiome – A diet rich in fiber, fruits, and vegetables; limit excess antibiotics.
• Manage autoimmune conditions – Keep associated diseases (e.g., thyroiditis) well‑controlled.

---

Complications

When untreated or poorly managed, microscopic colitis can lead to:

• Dehydration and electrolyte imbalance – Severe watery stool loss can cause hyponatremia, hypokalemia, or metabolic acidosis.
• Weight loss and malnutrition – Chronic diarrhea may impair nutrient absorption.
• Reduced quality of life – Social isolation, anxiety, and depression are common.
• Medication‑related complications – Long‑term systemic steroids increase risk of osteoporosis, diabetes, and infection.
• Rare progression to severe colitis – Though MC is considered “benign,” in rare cases patients develop overt inflammatory changes requiring hospitalization.

Prompt diagnosis and appropriate therapy dramatically lower these risks.

---

When to Seek Emergency Care

---

References

1. Mayo Clinic – Microscopic Colitis
2. CDC – Microscopic Colitis Overview
3. Cleveland Clinic – Microscopic Colitis
4. Miehlke et al., “Bud­esonide for Collagenous and Lymphocytic Colitis” (Gastroenterology, 2019)

```